@incollection{,
	
					
					
					97E474D50EB8AB92C17D15538501977C
				,
	author={{NightingaleSyabbalo}},
	journal={{Global Journal of Medical Research}},
	journal={{GJMR}}2249-46180975-588810.34257/GJMR,
	address={Cambridge, United States},
	publisher={Global Journals Organisation}2092740
}

@book{b0,
	
	
		,
	title={{Global Initiative for Asthma. Global Strategy for Asthma management and Prevention -updated 2020}}
		
		
			,
	year={April 2020}
		
	

}

@incollection{b1,
	
	
		,
	title={{Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). (Survey)}}
		,
	author={{
			NPearce
		} and {
			NAit-Khaled
		} and {
			RBeasley
		} and {
			JMallol
		} and {
			UKeil
		} and {
			EMitchell
		}}
		
		
		
		
		
	
	
		,
	journal={{Thorax}}
		
			62
			9
			758
			,
	year={2007}
		
	

}

@book{b2,
	
	
		,
	title={{The Global Asthma Network. The Global Asthma Report}}
		
		
			,
	year={2014. 2018}
		
	
	,
	note={Last accessed 07 August}

}

@incollection{b3,
	
	
		,
	title={{Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phase One and Three repeat multi-country cross-sectional surveys}}
		,
	author={{
			MIAsher
		} and {
			SMontefort
		} and {
			BBjorksten
		}}
		
		
	
	
		,
	journal={{Lancet}}
		
			368
			
			,
	year={2006}
		
	

}

@incollection{b4,
	
	
		,
	title={{Prevalence of asthma, allergic rhinitis, and eczema in 13-to-14 year-old children in Kuwait: an ISAAC study}}
		,
	author={{
			NBehbehani
		} and {
			AAbul
		} and {
			NCSyabbalo
		} and {
			AAzeem
		}}
		
		
		
		10.11016/s1081-1206(10)62435-0
	
	
		,
	journal={{Ann Allergy Asthma Immunol}}
		
			85
			1
			
			,
	year={2000}
		
	

}

@incollection{b5,
	
	
		,
	title={{Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics}}
		,
	author={{
			SEWenzel
		} and {
			LBSchwartz
		} and {
			ELLangmack
		} and {
			JLHalliday
		} and {
			JBTrudeau
		} and {
			RLGibbs
		}}
		
		
		
		
		
	
	
		,
	journal={{Am J Respir Crit Care Med}}
		
			160
			
			,
	year={1999}
		
	

}

@incollection{b6,
	
	
		,
	title={{Inflammatory subtypes in asthma: assessment and identification using induced sputum}}
		,
	author={{
			JLSimpson
		} and {
			RScott
		} and {
			MJBoyle
		} and {
			PGGibson
		}}
		
		
		
	
	
		,
	journal={{Respirology}}
		
			11
			1
			
			,
	year={2006}
		
	

}

@incollection{b7,
	
	
		,
	title={{Endotypying asthma: new insights into key pathogenic mechanism in a heterogenous disease}}
		,
	author={{
			GPAnderson
		}}
	
	
		,
	journal={{Lancet}}
		
			372
			
			,
	year={2008}
		
	

}

@incollection{b8,
	
	
		,
	title={{Asthma phenotypes: the evolution from clinical to molecular approach}}
		,
	author={{
			SEWenzel
		}}
	
	
		,
	journal={{Nat Med}}
		
			18
			
			,
	year={2012}
		
	

}

@incollection{b9,
	
	
		,
	title={{After asthma: redefining airways disease}}
		,
	author={{
			IDPavord
		} and {
			RBeasley
		} and {
			AAgusti
		}}
		
		
	
	
		,
	journal={{Lancet}}
		
			391
			
			,
	year={2018}
		
	

}

@incollection{b10,
	
	
		,
	title={{Understanding asthma phenotypes: the World Asthma Phenotypes (WASP) international collaboration}}
		,
	author={{
			LPembrey
		} and {
			MLBarreto
		} and {
			JDouwes
		} and {
			PCooper
		} and {
			JHendersen
		} and {
			HMpairwe
		} and {
			MArdura-Garcia
		} and {
			MChico
		}}
		
		
		
		
		
		
		
	
	
		,
	journal={{ERJ Open Res}}
		
			4
			3
			
			,
	year={2018}
		
	

}

@incollection{b11,
	
	
		,
	title={{Validated and longitudinally stable phenotypes based on cluster analysis of the ADEPT study}}
		,
	author={{
			MJLoza
		} and {
			RDjukanovic
		} and {
			KFChung
		} and {
			DHorowitz
		} and {
			KMa
		} and {
			PBranigan
		}}
		
		
		
		
		
		10.1186/s12931-016-0482-9
	
	
		,
	journal={{Respir Res}}
		
			17
			1
			165
			,
	year={2016}
		
	

}

@incollection{b12,
	
	
		,
	title={{U-BIOPRED clinical adult asthma cluster linked to a subset of sputum omics}}
		,
	author={{
			DLefaudeux
		} and {
			DeMeulder
		} and {
			BLoza
		} and {
			MJPeffer
		} and {
			NRowe
		} and {
			ABaribaud
		} and {
			F
		}}
		
		
		
		
		
		
		10.1016/j.jaci.2016.08.048
	
	
		,
	journal={{J Allergy Clin Immunol}}
		
			139
			6
			
			,
	year={2016}
		
	

}

@incollection{b13,
	
	
		,
	title={{Noneosinophilic asthma: a distinct clinical and pathologic phenotype}}
		,
	author={{
			PHaldar
		} and {
			IDPavord
		}}
		
	
	
		,
	journal={{J Allergy Clin Immunol}}
		
			119
			
			,
	year={2007}
		
	

}

@incollection{b14,
	
	
		,
	title={{Eosinophilic endotype of asthma}}
		,
	author={{
			FAleman
		} and {
			HFLim
		} and {
			PNair
		}}
		
		
	
	
		,
	journal={{Immunol Allergy North Am}}
		
			36
			3
			
			,
	year={2016}
		
	

}

@incollection{b15,
	
	
		,
	title={{Inflammatory phenotypes in patients with severe asthma are associated with distinct airway microbiology}}
		,
	author={{
			SLTaylor
		} and {
			LexLeong
		} and {
			JMChoo
		} and {
			SWesselingh
		} and {
			IAYang
		} and {
			JWUpham
		}}
		
		
		
		
		
	
	
		,
	journal={{J Allergy Clin Imnunol}}
		
			141
			1
			
			,
	year={2018}
		
	

}

@incollection{b16,
	
	
		,
	title={{National Asthma Education and Prevention Program. Guidelines for the Diagnosis and Management of Asthma}}
		,
	author={{
			PNtontsi
		} and {
			SLoukides
		} and {
			PBakakos
		} and {
			KKostikas
		} and {
			GPapatheodorou
		} and {
			EPapathanassiou
		} and {
			APapaporfyriou
		} and {
			EKonstantellou
		}}
		
		
		
		
		
		
		
		10.1183/13993003.congress-2016.PA4173.18
		
	
	
		,
	journal={{Eur Respir J}}
		
			18
			A4173
			,
	year={2016. October 28. 2019}
		
	
	,
	note={Clinical, functional and inflammatory characteristics in patients with paucigranulocytic asthma}

}

@incollection{b17,
	
	
		,
	title={{Management of severe asthma: A}}
		,
	author={{
			FHolguin
		} and {
			JCCardet
		} and {
			KFChung
		} and {
			SDiver
		} and {
			DSFerriera
		} and {
			AFitzpatrick
		} and {
			MGaga
		} and {
			LKellermeyer
		}}
		
		
		
		
		
		
		
		10.1183/13993003.0058-2019
	
	
		,
	journal={{Eur Respir J}}
		
			55
			1
			,
	year={2020}
			,
	publisher={American Thoracic Society}
		
	
	,
	note={guidelines}

}

@incollection{b18,
	
	
		,
	title={{Refractory airway type-2 inflammation in a large subgroup of asthmatics treated with inhaled corticosteroids}}
		,
	author={{
			MCPeters
		} and {
			SKerr
		} and {
			EMDuncan
		} and {
			PGWoodruff
		} and {
			MLFajt
		} and {
			BDLevy
		} and {
			IsrealEPhillips
		} and {
			BR
		}}
		
		
		
		
		
		
		
		10.1016/jaci.2017.12.1009
	
	
		,
	journal={{National Lung and Blood Institute Severe Asthma Research Program}}
		
			pii
			3
			
			,
	year={2018}
		
	
	,
	note={J Allergy Clin Immunol}

}

@incollection{b19,
	
	
		,
	title={{Changing roles of eosinophils in health and disease}}
		,
	author={{
			GTFutura
		} and {
			FDAtkins
		} and {
			NALee
		}}
		
		
	
	
		,
	journal={{Ann Allergy Asthma Immunol}}
		
			113
			
			,
	year={2014}
		
	

}

@incollection{b20,
	
	
		,
	title={{Eosinophilic granulomatosis with polyangitis (Churg-Stauss): state of the art}}
		,
	author={{
			AVaglio
		} and {
			CBuzio
		} and {
			JZwerina
		}}
		
		
	
	
		,
	journal={{Allergy}}
		
			68
			
			,
	year={2013}
		
	

}

@incollection{b21,
	
	
		,
	title={{Beiträge zur Kenntniss der granulirten Bindegewebszellen und der eosinophilen Leukocythen}}
		,
	author={{
			PEhrlich
		}}
	
	
		,
	journal={{Arch Anat Physiol (Leipzig)}}
		
			3
			
			,
	year={1879}
		
	

}

@incollection{b22,
	
	
		,
	title={{Zu Pathologie de Bronchia lasthma}}
		,
	author={{
			AFraenkel
		}}
	
	
		,
	journal={{Deutch Med Wchnschr}}
		
			17
			269
			,
	year={1900}
		
	

}

@incollection{b23,
	
	
		,
	title={{A clinical and pathophysiological study of fatal cases of status asthmaticus}}
		,
	author={{
			JCHouston
		} and {
			DeNavasquez
		} and {
			STrounce
		} and {
			JR
		}}
		
		
		
	
	
		,
	journal={{Thorax}}
		
			8
			
			,
	year={1953}
		
	

}

@incollection{b24,
	
	
		,
	title={{Eosinophilic inflammation in asthma}}
		,
	author={{
			JBousquet
		} and {
			PChanez
		} and {
			JYLacoste
		}}
		
		
	
	
		,
	journal={{N Engl J Med}}
		
			323
			
			,
	year={1990}
		
	

}

@incollection{b25,
	
	
		,
	title={{Eosinophil trafficking in allergy and asthma}}
		,
	author={{
			HFRosenberg
		} and {
			SPhipps
		} and {
			PSFoster
		}}
		
		
	
	
		,
	journal={{J Allergy Clin Immunol}}
		
			119
			6
			
			,
	year={2007}
		
	

}

@incollection{b26,
	
	
		,
	title={{Biology of eosinophils}}
		,
	author={{
			CBlanchard
		} and {
			MERothenberg
		}}
		
		.10.1016/S0065-2776(08)01003
	
	
		,
	journal={{Adv Immunol}}
		
			101
			
			,
	year={2009}
		
	

}

@incollection{b27,
	
	
		,
	title={{The biology of eosinophils and their role in asthma}}
		,
	author={{
			CNMcbrien
		} and {
			AMenzies-Gow
		}}
		
		10.3389/fmed
	
	
		,
	journal={{Front Med (Luasanne)}}
		
			4
			93
			,
	year={2017}
		
	

}

@incollection{b28,
	
	
		,
	title={{Novel combinatorial interactions of GATA-1, PU.1, and C/EBP episolon isoforms regulate transcription of the gene encoding eosinophil granule major basic protein}}
		,
	author={{
			JDu
		} and {
			MJStankiewicz
		} and {
			YLiu
		} and {
			QXi
		} and {
			JESchmidt
		} and {
			JALekstrom-Hime
		}}
		
		
		
		
		
		10.10074/jbcM204777.200
		
	
	
		,
	journal={{J Biol Chem}}
		
			277
			45
			
			,
	year={2002}
		
	

}

@incollection{b29,
	
	
		,
	title={{Immunology of asthma}}
		,
	author={{
			BNLambrecht
		} and {
			HHamad
		}}
		
		10.1038/ni.3049
	
	
		,
	journal={{Immunol}}
		
			16
			1
			
			,
	year={2015}
		
	

}

@incollection{b30,
	
	
		,
	title={{Asthma, allergy and chemokines}}
		,
	author={{
			JEPease
		}}
		doi: 10.2174/ 138945006775270204
	
	
		,
	journal={{Curr Drug Targets}}
		
			7
			
			,
	year={2006}
		
	

}

@incollection{b31,
	
	
		,
	title={{The chemokine, eotaxin, activates guinea-pig eosinophils in vitro and causes their accumulation into the lung in vivo}}
		,
	author={{
			DAGriffiths-Johnson
		} and {
			PDCollins
		} and {
			AGRossi
		} and {
			PJJose
		} and {
			TJWilliams
		}}
		
		
		
		
		doi: 10.1006 /bbrc.1993.2599
	
	
		,
	journal={{Biochem Biophys Res Commun}}
		
			197
			
			,
	year={1993}
		
	

}

@book{b32,
	
	
		,
	title={{Selective eosinophil transendothelial migration triggered by eotaxin via modulation of Mac-1/ICAM-1 and VLA}}
		,
	author={{
			G-QJia
		} and {
			J-AGonzale
		} and {
			AHidalgo
		} and {
			DWagner
		} and {
			MCybulsky
		} and {
			JCGutierrez-Ramos
		}}
		
		
		
		
		
		
	

}

@incollection{b33,
	
	
		,
	title={{/VCAM-1 interactions}}
		10.1093/intimm/11.1.1
	
	
		,
	journal={{In Immunol}}
		
			11
			
			,
	year={1999}
		
	

}

@incollection{b34,
	
	
		,
	title={{Eosinophil chemotactic chemokines (eotaxin-2, RANTES, monocyte chemo attractant protein-3 (MCP-3), and MCP-4, and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (intrinsic) asthmatics}}
		,
	author={{
			SYing
		} and {
			QMeng
		} and {
			RZeibecoglou
		} and {
			DSRobinson
		} and {
			AMacfarlane
		} and {
			MHumbert
		}}
		
		
		
		
		
	
	
		,
	journal={{J Immunol}}
		
			163
			11
			
			,
	year={1999}
		
	

}

@incollection{b35,
	
	
		,
	title={{Up-regulation and activation of eosinophil integrin in blood and airway after segmental lung allergen challenge}}
		,
	author={{
			MWJohannson
		} and {
			EAKelly
		} and {
			WWBusse
		} and {
			NNJajour
		} and {
			DFMosher
		}}
		
		
		
		
	
	
		,
	journal={{J Immunol}}
		
			,
	year={2008}
		
	

}

@book{b36,
	
	
		,
	title={{}}
		10.4049/jimmunol.180.11.7622
		
			180
			
		
	

}

@incollection{b37,
	
	
		,
	title={{The role of eosinophils in host defense against helminth parasites}}
		,
	author={{
			ADKlion
		} and {
			TBNutman
		}}
		
		10.1016/j.jaci.2003.10.050
	
	
		,
	journal={{J Allergy Clin Immunol}}
		
			113
			
			,
	year={2004}
		
	

}

@incollection{b38,
	
	
		,
	title={{The early history of the eosinophil}}
		,
	author={{
			ABKay
		}}
	
	
		,
	journal={{Clin Exp Allergy}}
		
			45
			
			,
	year={2015}
		
	

}

@incollection{b39,
	
	
		,
	title={{The expanding role(s) of eosinophils in health and disease}}
		,
	author={{
			EJacobson
		} and {
			RAHelmer
		} and {
			JJLee
		} and {
			NALee
		}}
		
		
		
		10.1182/blood-2012-06-330845.
		
	
	
		,
	journal={{Blood}}
		
			120
			
			,
	year={2012}
		
	

}

@incollection{b40,
	
	
		,
	title={{Human eosinophils constitutively express multiple Th1, Th2 and immunoregulatory cytokines that are secreted rapidly and differentially}}
		,
	author={{
			LASpencer
		} and {
			CTSzela
		} and {
			SAPerez
		}}
		
		
	
	
		,
	journal={{J Leukoc Biol}}
		
			,
	year={2009}
		
	

}

@incollection{b41,
	
	
		,
	title={{The cellular biology of eosinophil eicosanoid formation and function}}
		,
	author={{
			CBandeira-Melo
		} and {
			PTBozza
		} and {
			PFWeller
		}}
		
		
		10.1067/mai.2002.121529
	
	
		,
	journal={{J Allergy Clin Immunol}}
		
			109
			3
			
			,
	year={2002}
		
	

}

@incollection{b42,
	
	
		,
	title={{Innate lymphoid cells: how did we miss them?}}
		,
	author={{
			JAWalker
		} and {
			JLBarlow
		} and {
			AMMckenzie
		}}
		
		
		10.1038/nri3349
	
	
		,
	journal={{Nat Rev Immunol}}
		
			13
			
			,
	year={2013}
		
	

}

@incollection{b43,
	
	
		,
	title={{Increased numbers of activated group 2 innate lymphoid cells in airways of patients with severe asthma and persistent airway eosinophilia}}
		,
	author={{
			SGSmith
		} and {
			RChen
		} and {
			MKjarsgaard
		} and {
			CHuang
		} and {
			JPOliveria
		} and {
			OByrne
		} and {
			PM
		}}
		
		
		
		
		
		
		10.1016/j.jaci.2015.05.037
		
	
	
		,
	journal={{J Allergy Clin Immunol}}
		
			137
			
			,
	year={2016}
		
	

}

@incollection{b44,
	
	
		,
	title={{Allergic diseases: from bench to cliniccontribution of the discovery of IL-5}}
		,
	author={{
			TYanagibashi
		} and {
			TMSatoh
		} and {
			YNagai
		} and {
			MKoike
		} and {
			KTakatsu
		}}
		
		
		
		
		10.1016/j.cyto.2016.11.011
	
	
		,
	journal={{Cytokine}}
		
			98
			
			,
	year={2017}
		
	

}

@incollection{b45,
	
	
		,
	title={{The cytokines of asthma}}
		,
	author={{
			BNLambrecht
		} and {
			HHammad
		} and {
			JVFahy
		}}
		
		
		10.1016/j.immuni.2019.03.018
		
	
	
		,
	journal={{Immunity}}
		
			50
			
			,
	year={2019}
		
	

}

@incollection{b46,
	
	
		,
	title={{The immunology of asthma}}
		,
	author={{
			BNLambrecht
		} and {
			HHammad
		}}
		
		10.1038/ni.3049
	
	
		,
	journal={{Nat Immunol}}
		
			16
			
			,
	year={2015}
		
	

}

@incollection{b47,
	
	
		,
	title={{A novel dimer configuration revealed by the crystal structure at 2.4 Å resolution of human interleukin-5}}
		,
	author={{
			MVMilburn
		} and {
			AMHassell
		} and {
			MHLambert
		}}
		
		
		10.1038/3631/72a0
	
	
		,
	journal={{Nature}}
		
			363
			6425
			
			,
	year={1993}
		
	

}

@book{b48,
	
	
		,
	title={{Interleukin-5 and the interleukin receptor: target for drug discovery in asthma}}
		,
	author={{
			MMckinnon
		} and {
			MBank
		} and {
			RSolari
		} and {
			GRobinson
		}}
		
		
		
		,
	editor={Sanderson C.}
		
			,
	year={1999}
			,
	publisher={Marcel Dekker, Inc}
			
			,
	address={New York}
		
	
	,
	note={Interleukin-5: From Molecule to Drug Target for asthma}

}

@incollection{b49,
	
	
		,
	title={{Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics}}
		,
	author={{
			AMenzies-Gow
		} and {
			PFlood-Page
		} and {
			RSehmi
		} and {
			JBurman
		} and {
			QHamid
		} and {
			DRobinson
		}}
		
		
		
		
		
	
	
		,
	journal={{J Allergy Clin Immunol}}
		
			111
			
			,
	year={2003}
		
	

}

@incollection{b50,
	
	
		,
	title={{Th2 cytokines and asthma -The role of interleukin-5 in allergic eosinophilic disease}}
		,
	author={{
			SGreenfender
		} and {
			SPUmland
		} and {
			FMCuss
		} and {
			RWChapman
		} and {
			RWEgan
		}}
		
		
		
		
	
	
		,
	journal={{Respir Res}}
		
			2
			
			,
	year={2001}
		
	

}

@incollection{b51,
	
	
		,
	title={{Human interleukin-5 (IL-5) regulates the production in bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF}}
		,
	author={{
			EClutterbuck
		} and {
			EHirst
		} and {
			CSanderson
		}}
		
		
	
	
		,
	journal={{Blood}}
		
			,
	year={1989}
		
	

}

@incollection{b52,
	
	
		,
	title={{IL-5-and eosinophil-mediated inflammation: from discovery to therapy}}
		,
	author={{
			TKouro
		} and {
			LTakatsu
		}}
		
		10.1093/intimm/dxp102
	
	
		,
	journal={{Int Immun}}
		
			21
			12
			
			,
	year={2009}
		
	

}

@incollection{b53,
	
	
		,
	title={{The mechanism of IL-5 signal transduction}}
		,
	author={{
			TAdachi
		} and {
			RAlam
		}}
		
	
	
		,
	journal={{Am J Physiol}}
		
			275
			3
			
			,
	year={1998}
		
	
	,
	note={Pt 1}

}

@incollection{b54,
	
	
		,
	title={{Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor}}
		,
	author={{
			NAMolfino
		} and {
			DGossage
		} and {
			RKolbeck
		} and {
			JMParker
		} and {
			GPGeba
		}}
		
		
		
		
		10.1111/j.1365-2222.2011.03854.x
	
	
		,
	journal={{Clin Exp Allergy}}
		
			42
			
			,
	year={2012}
		
	

}

@incollection{b55,
	
	
		,
	title={{The interleukin-5/receptor interaction activates Lyn and JAK2 tyrosine kinase and signals via Ras-Raf-1-MAP kinase and the JAK-STAT pathway in eosinophils}}
		,
	author={{
			RAlam
		} and {
			Pazdrak
		} and {
			SStafford
		} and {
			PForsythe
		}}
		
		
		
		10.1017/CBO97811074/5324.004
	
	
		,
	journal={{Int Arch Allergy Immunol}}
		
			107
			
			,
	year={1995}
		
	

}

@incollection{b56,
	
	
		,
	title={{Jak2, and Raf-I kinases are critical for the antiapoptotic effect of interleukin-5, wheras only Raf-1 kinase is essential for eosinophil activation and degranulation}}
		,
	author={{
			KPazdrak
		} and {
			BOlszewska-Pazdrak
		} and {
			SStafford
		} and {
			RPGarofalo
		} and {
			AlamRLyn
		}}
		
		
		
		
		10.1084/jem.188.3.421
	
	
		,
	journal={{J Exp Med}}
		
			188
			
			,
	year={1998}
		
	

}

@incollection{b57,
	
	
		,
	title={{Regulation of interleukin-5-induced beta2-integrin adhesion of human eosinophils by phosphoinositide 3-kinase}}
		,
	author={{
			MSano
		} and {
			ARLeff
		} and {
			SMyou
		} and {
			EBoetticher
		} and {
			AYMeliton
		} and {
			JLearoyd
		}}
		
		
		
		
		
		10.1165/rcmb.2005-0076OC
	
	
		,
	journal={{Am J Respir Cell Mol Biol}}
		
			33
			
			,
	year={2005}
		
	

}

@incollection{b58,
	
	
		,
	title={{The differential role of extracellular signal-regulated kinases and p38 mitogenic-activated protein kinase in eosinophil functions}}
		,
	author={{
			TAdachi
		} and {
			BKChoudhuri
		} and {
			SStafford
		} and {
			SSur
		} and {
			RAlam
		}}
		
		
		
		
		10.4049/jimmunol.165.4.2198
	
	
		,
	journal={{J Immunol}}
		
			165
			
			,
	year={2000}
		
	

}

@incollection{b59,
	
	
		,
	title={{Interleukin-3, -3, and granulocyte macrophage colony-stimulating factor induce adhesion and chemotaxis of human eosinophils via p38 mitogenactivated proten kinase and nuclear factor kappaB}}
		,
	author={{
			WKIp
		} and {
			CKWong
		} and {
			CBWang
		} and {
			YPTian
		} and {
			CWLam
		}}
		
		
		
		
		10.1080/08923970500240925
	
	
		,
	journal={{Immunopharmacol Immunotoxicol}}
		
			27
			
			,
	year={2005}
		
	

}

@incollection{b60,
	
	
		,
	title={{The role of interleukin 5 in asthma}}
		,
	author={{
			GVarrichi
		} and {
			GWCononica
		}}
		
		10.1080/1744666X.2016.1208564
		
	
	
		,
	journal={{Exp Rev Clin Immunol}}
		
			12
			
			,
	year={2016}
		
	

}

@incollection{b61,
	
	
		,
	title={{Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs}}
		,
	author={{
			GVarricchi
		} and {
			DBagnasco
		} and {
			FBorrielo
		} and {
			EHeffler
		} and {
			GWConanica
		}}
		
		
		
		
		10.1097/ACI.0000000000000251
	
	
		,
	journal={{Curr Opin Allergy Clin Immunol}}
		
			16
			
			,
	year={2016}
		
	

}

@incollection{b62,
	
	
		,
	title={{A review of three antiinterleukin-5 monoclonal antibody therapies for severe asthma}}
		,
	author={{
			VCAgumadu
		} and {
			KRamphul
		} and {
			SGMejias
		} and {
			RSonaye
		} and {
			SSombans
		} and {
			PLohana
		}}
		
		
		
		
		
		10.7759/cureus.3216
	
	
		,
	journal={{Cureus}}
		
			10
			8
			e3216
			,
	year={2018}
		
	

}

@incollection{b63,
	
	
		,
	title={{Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys}}
		,
	author={{
			PZia-Amirhosseini
		} and {
			EMinthorn
		} and {
			LBenincosa
		} and {
			THart
		} and {
			CHottenstein
		} and {
			LTobias
		}}
		
		
		
		
		
	
	
		,
	journal={{J Pharmacol Exp Ther}}
		
			291
			
			,
	year={1999}
		
	

}

@incollection{b64,
	
	
		,
	title={{Recombinant human interleukin 5 is a selective activator of human eosinophil function}}
		,
	author={{
			ALopez
		} and {
			CSanderson
		} and {
			JGamble
		} and {
			HCampbell
		} and {
			IYoung
		} and {
			MVadas
		}}
		
		
		
		
		
	
	
		,
	journal={{J Exp Med}}
		
			167
			
			,
	year={1988}
		
	

}

@incollection{b65,
	
	
		,
	title={{Eosinophil survival activity identified as interleukin-5 is associated with eosinophil recruitment and degranulation and lung injury twenty-four hours after segmental antigen lung challenge}}
		,
	author={{
			TOhnishi
		} and {
			SSur
		} and {
			DCollins
		} and {
			JFish
		} and {
			GGleich
		} and {
			SPeters
		}}
		
		
		
		
		
	
	
		,
	journal={{J Allergy Clin Immunol}}
		
			92
			
			,
	year={1993}
		
	

}

@incollection{b66,
	
	
		,
	title={{Technology evaluation: mepolizumab, GlaxoSmithKline}}
		,
	author={{
			GGnanakumaran
		} and {
			KSBabu
		}}
		
	
	
		,
	journal={{Curr Opin Ther}}
		
			5
			
			,
	year={2003}
		
	

}

@incollection{b67,
	
	
		,
	title={{Anti-IL-5 and IL-5R: efficacy and safety of new therapeutic strategies in severe uncontrolled asthma}}
		,
	author={{
			DBagnasco
		} and {
			MCaminati
		} and {
			MFerrando
		} and {
			TAloè
		} and {
			ETestino
		} and {
			GWCanonica
		}}
		
		
		
		
		
		5698212.10.1155/2018/5698212
	
	
		,
	journal={{Biomed Res}}
		
			,
	year={2018}
		
	

}

@incollection{b68,
	
	
		,
	title={{Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper responsiveness, and the late asthmatic response}}
		,
	author={{
			MJLeckie
		} and {
			ATen Brinke
		} and {
			JKhan
		} and {
			ZDiamant
		} and {
			O'Connor
		} and {
			BJWalls
		} and {
			CM
		}}
		
		
		
		
		
		
		10.1016/50140-6736(00)03496-6
	
	
		,
	journal={{Lancet}}
		
			356
			
			,
	year={2000}
		
	

}

@incollection{b69,
	
	
		,
	title={{Mepolizumab for severe asthma (DREAM): a multicenter, double-blind, placebocontrolled trial}}
		,
	author={{
			IDPavord
		} and {
			SKorns
		} and {
			PHowarth
		} and {
			ERBleecker
		} and {
			LBuhl
		} and {
			ONKeene
		}}
		
		
		
		
		
		10.1916/S0140-6736(12)60988-X
	
	
		,
	journal={{Lancet}}
		
			380
			
			,
	year={2012}
		
	

}

@incollection{b70,
	
	
		,
	title={{Mepolizumab treatment in patients with severe eosinophilic asthma}}
		,
	author={{
			HGOrtega
		} and {
			MCLiu
		} and {
			IDPavord
		} and {
			GGBrusselle
		} and {
			JMFitzgerald
		} and {
			SChetta
		}}
		
		
		
		
		
		10.1056/NEJMoa1403290
	
	
		,
	journal={{N Engl J Med}}
		
			371
			
			,
	year={2014}
		
	

}

@incollection{b71,
	
	
		,
	title={{Oral glucocorticoidsparing effect of mepolizumab in eosinophilic asthma}}
		,
	author={{
			EHBel
		} and {
			SEWenzel
		} and {
			PJThompson
		} and {
			CMPrazma
		} and {
			ONKeene
		} and {
			SWYancey
		}}
		
		
		
		
		
		10.1056/NEJMoa1403291
	
	
		,
	journal={{N Engl J Med}}
		
			371
			
			,
	year={2014}
		
	

}

@incollection{b72,
	
	
		,
	title={{Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomized, double-blind, placebo-controlled, parallel-group, multi-center, phase 3b trial}}
		,
	author={{
			GLChupp
		} and {
			ESBradford
		} and {
			FCAlbers
		} and {
			DJBratton
		} and {
			JWang-Jairaj
		} and {
			LMNelsen
		}}
		
		
		
		
		
		10.1016/S2213-2600
	
	
		,
	journal={{Lancet Respir Med}}
		
			5
			30125
			,
	year={2017}
		
	

}

@book{b73,
	
	
		,
	title={{Food and Drug Administration}}
		,
	author={{
			SilverSpring
		} and {
			USMd
		}}
		
		
		
			,
	year={November 4, 2015. January 7. 2016}
		
	

}

@incollection{b74,
	
	
		,
	title={{}}
		,
	author={{
			(Nucala
		} and {
			Mepolizumab
		}}
		
	
	
		,
	journal={{European Medicine Agency}}
		
			,
	year={January, 2019}
		
	
	,
	note={Accessed}

}

@incollection{b75,
	
	
		,
	title={{Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5}}
		,
	author={{
			JZhang
		} and {
			RKuvelkar
		} and {
			NJMurgolo
		} and {
			SSTaremi
		} and {
			CCChou
		} and {
			PWang
		}}
		
		
		
		
		
		10.1093/intimm/11.12.1935
		
	
	
		,
	journal={{Int Immunol}}
		
			11
			12
			
			,
	year={1999}
		
	

}

@incollection{b76,
	
	
		,
	title={{Effect of SCH55700, a humanized antihuman anterleukin-5 antibody, in severe persistent asthma. A pilot study}}
		,
	author={{
			JCKips
		} and {
			BJConnor
		} and {
			SJLangley
		} and {
			AWoodcock
		} and {
			HAKerstjens
		} and {
			DSPostma
		}}
		
		
		
		
		
		10.1164/rccm.200206-525OC
		
	
	
		,
	journal={{Am J Respir Crit Care Med}}
		
			167
			
			,
	year={2003}
		
	

}

@incollection{b77,
	
	
		,
	title={{Reslizumab for poorly controlled asthma: a randomized, placebo-controlled study}}
		,
	author={{
			MCastro
		} and {
			SMathur
		} and {
			FHargreave
		} and {
			LPBoulet
		} and {
			FXie
		} and {
			JYoung
		}}
		
		
		
		
		
		1125-1132.10.1164/rccm.201103-0396OC
	
	
		,
	journal={{Am J Respir Crit Care Med}}
		
			184
			10
			,
	year={2011}
		
	

}

@incollection{b78,
	
	
		,
	title={{Reslizumab for inadequately controlled asthma with elevated eosinophil count: results from two multicentre, parallel, double-blind, randomised, placebocontrolled, phase 3 trials}}
		,
	author={{
			MCastro
		} and {
			JZangrilli
		} and {
			MEWechsler
		} and {
			EDBateman
		} and {
			GGBrusselle
		} and {
			PBardin
		}}
		
		
		
		
		
		10.1016/S2213-2600(15)00042-9
	
	
		,
	journal={{Lancet Respir Med}}
		
			3
			
			,
	year={2015}
		
	

}

@incollection{b79,
	
	
		,
	title={{Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study}}
		,
	author={{
			LBjermer
		} and {
			CLemiere
		} and {
			JMaspero
		} and {
			SWeiss
		} and {
			JZangrilli
		} and {
			MGerminaro
		}}
		
		
		
		
		
		10.1016/j.chest.2016.03.032
	
	
		,
	journal={{Chest}}
		
			150
			
			,
	year={2016}
		
	

}

@incollection{b80,
	
	
		,
	title={{Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils}}
		,
	author={{
			GBrusselle
		} and {
			MGerminaro
		} and {
			SWeiss
		} and {
			JZangrilli
		}}
		
		
		
		10.1016/j.pupt.2017.01.011
	
	
		,
	journal={{Pulm Pharmacol Ther}}
		
			43
			
			,
	year={2017}
		
	

}

@book{b81,
	
	
		,
	title={{Food and Drug Administration}}
		,
	author={{
			SilverSpring
		} and {
			USMd
		}}
		
		
		
			,
	year={March 23. 2016. 2016}
			8
		
	

}

@book{b82,
	
	
		,
	title={{Reslizumab (Cingaero® (reslizumab)}}
		,
	author={{
			LtdTeva Pharmaceutical
		}}
		
		
			,
	year={2006. Mar 2017}
		
	

}

@incollection{b83,
	
	
		,
	title={{Kinetic interaction analysis of human interleukin 5 receptor ? mutants reveals a unique binding topology and charge distribution for cytokine recognition}}
		,
	author={{
			TIshino
		} and {
			GPasut
		} and {
			JScibek
		} and {
			IChaiken
		}}
		
		
		
		10.1074/jbc.M309327200
	
	
		,
	journal={{J Biol Chem}}
		
			279
			
			,
	year={2004}
		
	

}

@incollection{b84,
	
	
		,
	title={{Medi-563, a humanized anti-IL-5 receptor ? mAb with enhanced antibody-dependent cell mediated cytotoxicity function}}
		,
	author={{
			RKolbeck
		} and {
			AKozhich
		} and {
			MKoike
		} and {
			LPeng
		} and {
			CKAndersson
		} and {
			MMDamschroder
		}}
		
		
		
		
		
		10.1016/j.jaci.2010.04.004
	
	
		,
	journal={{J Allergy Clin Immunol}}
		
			125
			
			,
	year={2010}
		
	

}

@incollection{b85,
	
	
		,
	title={{Interleukin-5 in the pathophysiology of severe asthma}}
		,
	author={{
			CPelaia
		} and {
			GPaoletti
		} and {
			FPuggioni
		} and {
			FRacca
		} and {
			GPelaia
		} and {
			GWCanonica
		} and {
			EHeffler
		}}
		
		
		
		
		
		
		10.3389/fphys.2019.01514
	
	
		,
	journal={{Front Physiol}}
		
			10
			1514
			,
	year={2019}
		
	

}

@incollection{b86,
	
	
		,
	title={{Lack of fucose on human IgG1 Nlinked oligosaccharide improves binding to Fcgamma RIII and antibody-dependent cellular toxicity}}
		,
	author={{
			RLShields
		} and {
			JLai
		} and {
			RKeck
		} and {
			OConnell
		} and {
			LYHong
		} and {
			KMeng
		} and {
			YG
		}}
		
		
		
		
		
		
		10.1074/jbc.M202069200
	
	
		,
	journal={{J Biol Chem}}
		
			277
			
			,
	year={2002}
		
	

}

@incollection{b87,
	
	
		,
	title={{Benralizumab -a humanized mAb to IL-5 with enhanced antibodydependent cell-mediated cytotoxicity -a novel approach for the treatment of asthma}}
		,
	author={{
			AGhazi
		} and {
			ATrikha
		} and {
			WJCalhoun
		}}
		
		
		10.1517/14712598.2012.642359
	
	
		,
	journal={{Expert Opin Biol Ther}}
		
			12
			
			,
	year={2012}
		
	

}

@incollection{b88,
	
	
		,
	title={{}}
		,
	author={{
			DBagnasco
		} and {
			MFerrando
		} and {
			GVarricchi
		} and {
			FPuggioni
		} and {
			GPassalacqua
		} and {
			GWCanonica
		}}
		
		
		
		
		
	
	
		,
	journal={{Anti-interleukin}}
		
			5
		
	

}

@incollection{b89,
	
	
		,
	title={{IL-5Ra: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma}}
		doi: 10.3389/ fmed.2017.00135
	
	
		,
	journal={{Front Med (Lausanne)}}
		
			4
			135
			,
	year={2017}
		
	

}

@incollection{b90,
	
	
		,
	title={{Benralizumab: a unique IL-5 inhibitor for severe asthma}}
		,
	author={{
			LDTan
		} and {
			JMBratt
		} and {
			DGodor
		} and {
			SLouie
		} and {
			NJKenyon
		}}
		
		
		
		
		10.2147/JAA.S78049
	
	
		,
	journal={{J Asthma Allergy}}
		
			9
			
			,
	year={2016}
		
	

}

@incollection{b91,
	
	
		,
	title={{Benralizumab, an anti-interleukin 5 receptor ? monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomized study}}
		,
	author={{
			MCastro
		} and {
			SEWenzel
		} and {
			RBleecker
		}}
		
		
	
	
		,
	journal={{Lancet}}
		
			2
			
			,
	year={2014}
		
	

}

@incollection{b92,
	
	
		,
	title={{Effect of benralizumab on airway eosinophil in asthmatic patients with sputum eosinophilia}}
		,
	author={{
			MLaviolette
		} and {
			DLGossage
		} and {
			GGauvreau
		} and {
			RLeigh
		} and {
			ROlivenstein
		} and {
			RKatail
		}}
		
		
		
		
		
		10.1016/j.jaci.2013.05.020
	
	
		,
	journal={{J Allergy Clin Immunol}}
		
			132
			5
			
			,
	year={2013}
		
	

}

@incollection{b93,
	
	
		,
	title={{Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dose inhaled corticosteroids and long-acting ?-agonists (SIROCCO): a randomized multicentre}}
		,
	author={{
			ERBleecker
		} and {
			JMFitgerald
		} and {
			PChanez
		} and {
			APapi
		} and {
			SFWeinstein
		} and {
			PBaker
		}}
		
		
		
		
		
		10.1016/S0140-6736
	
	
		,
	journal={{Lancet}}
		
			388
			16
			
			,
	year={2016}
		
	

}

@incollection{b94,
	
	
		,
	title={{Benralizumab, an antiinterleukin-5 receptor monoclonal antibody, as addon treatment for patients with severe asthma, uncontrolled eosinophilic asthma (CALIMA): a randomized, double-blind}}
		,
	author={{
			JMFitzgerald
		} and {
			ERBleecker
		} and {
			PNair
		} and {
			SKorn
		} and {
			SOhta
		} and {
			MLommatzsch
		}}
		
		
		
		
		
	
	
		,
	journal={{Lancet}}
		
			388
			
			,
	year={2016}
		
	

}

@book{b95,
	
	
		,
	title={{}}
		10.1016/S0140-6736(16)31322
		
			
		
	

}

@incollection{b96,
	
	
		,
	title={{Predictors of enhanced response with benralizumab for patients with severe asthma: Pooled analysis of the SIROCCO and CALIMA studies}}
		,
	author={{
			JMFitzgerald
		} and {
			ERBleecker
		} and {
			AMenzies-Gow
		} and {
			JGZangrill
		} and {
			IHirch
		} and {
			PMetcalfe
		} and {
			PNewbold
		} and {
			MGoldman
		}}
		
		
		
		
		
		
		
		doi: 10.16/S2213-2600
	
	
		,
	journal={{Lancet Respir Med}}
		
			6
			
			,
	year={2018}
		
	

}

@incollection{b97,
	
	
		,
	title={{Oral glucocorticoid-sparing effect of benralizumab in severe asthma}}
		,
	author={{
			PNair
		} and {
			SWenzel
		} and {
			KFRabe
		} and {
			ABourdin
		} and {
			NLLugogo
		} and {
			PKuna
		}}
		
		
		
		
		
		10.1056/NEJMoa1703501
	
	
		,
	journal={{N Engl J Med}}
		
			375
			
			,
	year={2017}
		
	

}

@incollection{b98,
	
	
		,
	title={{Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial}}
		,
	author={{
			EBusse
		} and {
			RBleecker
		} and {
			JMFitzgerald
		} and {
			GTFerguson
		} and {
			PBarker
		} and {
			SSproule
		}}
		
		
		
		
		
		10.1016/S2213-2600(18)30406-5
	
	
		,
	journal={{Lancet Respir Med}}
		
			7
			
			,
	year={2019}
		
	

}

@incollection{b99,
	
	
		,
	title={{Real-life rapidity of benralizumab effects in patients with severe allergic asthma: assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose}}
		,
	author={{
			CPelaia
		} and {
			MTBusceti
		} and {
			AVatrella
		} and {
			GFRago
		} and {
			CCrimi
		} and {
			RTerracciano
		}}
		
		
		
		
		
		58101830.10.1016/j.pupt.2019.101830
	
	
		,
	journal={{Pulm Pharmacol Ther}}
		
			,
	year={2019}
		
	

}

@incollection{b100,
	
	
		,
	title={{Biomarkers in the management of difficult asthma}}
		,
	author={{
			FSchleich
		} and {
			DSophie
		} and {
			LRenaud
		}}
		
		
	
	
		,
	journal={{Curr Top Med Chem}}
		
			16
			22
			2521
			,
	year={2016}
		
	

}

@incollection{b101,
	
	
		,
	title={{Biomarkers in severe asthma}}
		,
	author={{
			XCWan
		} and {
			PGWoodruff
		}}
		
	
	
		,
	journal={{Immunol Allergy North Am}}
		
			36
			3
			
			,
	year={2016}
		
	

}

@incollection{b102,
	
	
		,
	title={{Biomarkers in asthma}}
		,
	author={{
			SWYancy
		} and {
			ONKeene
		} and {
			FCAlbers
		} and {
			HOrtega
		} and {
			SBates
		} and {
			ERBleecker
		} and {
			IPavord
		}}
		
		
		
		
		
		
		10.1016/j.jaci.2017.10.005
	
	
		,
	journal={{J Allergy Clin Immunol}}
		
			140
			6
			
			,
	year={2017}
		
	

}

@incollection{b103,
	
	
		,
	title={{Biomarker in asthma. State of the art}}
		,
	author={{
			ATiotiua
		}}
	
	
		,
	journal={{Asthma Res Pract}}
		
			4
			10
			,
	year={2018}
		
	

}

@incollection{b104,
	
	
		,
	title={{Biomarkers for the diagnosis and management of eosinophilic asthma}}
		,
	author={{
			NSyabbalo
		}}
	
	
		,
	journal={{Ann Clin Med Res}}
		
			1
			1003
			,
	year={2020}
		
	

}

@incollection{b105,
	
	
		,
	title={{Effects of adding omalizumab, an antiimmunoglobulin E antibody, on airway wall thickening in asthma}}
		,
	author={{
			MHoshino
		} and {
			JOhtawa
		}}
		
	
	
		,
	journal={{Respiration}}
		
			83
			
			,
	year={2012}
		
	

}

@incollection{b106,
	
	
		,
	title={{Omalizumab modulates bronchial reticular basement membrane and eosinophilic infiltration in severe persistent allergic asthma patients}}
		,
	author={{
			ARiccio
		} and {
			RDal Negro
		} and {
			CMicheletto
		} and {
			DeFerrari
		} and {
			LFolli
		} and {
			CChiappori
		} and {
			A
		}}
		
		
		
		
		
		
	
	
		,
	journal={{Int J Immunopathol Pharmacol}}
		
			25
			
			,
	year={2012}
		
	

}

@incollection{b107,
	
	
		,
	title={{Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin}}
		,
	author={{
			SPhipps
		} and {
			PFlood-Page
		} and {
			AMenzies-Gow
		} and {
			YOng
		} and {
			AKay
		}}
		
		
		
		
	
	
		,
	journal={{J Invest Dermatol}}
		
			122
			
			,
	year={2004}
		
	

}

@incollection{b108,
	
	
		,
	title={{Management of severe asthma: A}}
		,
	author={{
			FHolguin
		} and {
			JCCardet
		} and {
			KFChung
		} and {
			SDiver
		} and {
			DSFerriera
		} and {
			AFitzpatrick
		} and {
			MGaga
		} and {
			LKellermeyer
		}}
		
		
		
		
		
		
		
		10.1183/13993003.0058-2019
	
	
		,
	journal={{Eur Respir J}}
		
			55
			1
			,
	year={2020}
			,
	publisher={American Thoracic Society}
		
	
	,
	note={guidelines}

}

@incollection{b109,
	
	
		,
	title={{Cost-effectiveness of refractory asthma treatment strategies: a decision tree analysis}}
		,
	author={{
			MBogart
		} and {
			ARoberts
		} and {
			SWheeler
		}}
		
		
	
	
		,
	booktitle={{ISPOR 20 th Annual Meeting}}
				Philadelphia, PA, USA
		
	

}

@incollection{b110,
	
	
		,
	title={{Indirect comparison of bronchial thermoplasty versus omalizumab for uncontrolled asthma}}
		,
	author={{
			RMNiven
		} and {
			MRSimmonds
		} and {
			MJCangelosi
		} and {
			DPTilden
		} and {
			SCottrell
		} and {
			NSShargill
		}}
		
		
		
		
		
		10.1080/02770903.2017.1337789136
	
	
		,
	journal={{J Asthma}}
		
			55
			4
			
			,
	year={2017}
		
	

}

@incollection{b111,
	
	
		,
	title={{Bronchial thermoplasty in severe asthma: best practice recommendations from an expert panel}}
		,
	author={{
			PIBonta
		} and {
			PChanez
		} and {
			JTAnnema
		} and {
			PIShah
		} and {
			RNiven
		}}
		
		
		
		
		org/10.11 59/000488291
	
	
		,
	journal={{Respiration}}
		
			95
			
			,
	year={2018}
		
	

}

@incollection{b112,
	
	
		,
	title={{Emerging understanding of the mechanism of action of bronchial thermoplasty in asthma}}
		,
	author={{
			JnsD'hooghe
		} and {
			TenHacken
		} and {
			NhtWeersink
		} and {
			EjmSterk
		} and {
			PJAnnema
		} and {
			JTBonta
		} and {
			PI
		}}
		
		
		
		
		
		
	
	
		,
	journal={{Pharmacol Ther}}
		
			181
			
			,
	year={2018}
		
	

}

@incollection{b113,
	
	
		,
	title={{Bronchial thermoplasty as a treatment for severe asthma: controversies, progress and uncertainties}}
		,
	author={{
			NCThomson
		}}
		10.1080/17476348.2018.1444991
	
	
		,
	journal={{Exp Rev Respir Med}}
		
			12
			4
			
			,
	year={2018}
		
	

}

@incollection{b114,
	
	
		,
	title={{Clinical features and management of neutrophilic asthma}}
		,
	author={{
			NSyabbalo
		}}
		10.24966/PMRR-0177/100036
	
	
		,
	journal={{J Pulm Med Respir Res}}
		
			6
			36
			,
	year={2020}
		
	

}

@book{b115,
	
	
		,
	title={{Table 1: Pro-inflammatory mediators synthesized and secreted by eosinophils Major basic protein (MBP)}}
		
	

}

@book{b116,
	
	
		,
	author={{
			Gm-CsfTnf-?
		} and {
			Chemokines
		}}
		
		,
	title={{Eosinophil cationic protein (ECP) Eosinophil-derived neurotoxin (EDN) Eosinophil-derived peroxide (EDPX) Reactive oxygen species: superoxide, peroxide, and hypobromite Prostaglandins: PGD2 Cysteinyl leukotrienes: LTC4, LTD4, LTE4 Throboxane B2: TXB2 Platelet activating factor (PAF) Cytokines}}
				IL-2, IL-3, IL-4, IL-5, IL-9, IL-13, IL-23, IL-25, IL-33
		
	
	,
	note={eotaxin-1, -2, and -3, RANTES, P-selectin, MIP-1, MCP-3, MCP-4}

}

@incollection{b117,
	
	
	
	
		,
	booktitle={{Enzymes: histaminases, arylsulfatase, MMP-9}}
				VEGF, PDGF
		
	

}